Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials
Open accessThe DOI matches its Crossref record; 81 of the 83 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The comparison between long acting insulin analogues (LAIA) and human insulin (NPH) has been investigated for decades, with many randomized controlled trials (RCTs) and systematic reviews giving mixed results. This overlapping and contradictory evidence has increased uncertainty on coverage decisions at health systems level. AIM: To conduct an overview of systematic reviews and update existing reviews, preparing new meta-analysis to determine whether LAIA are effective for T1D patients compared to NPH. METHODS: We identified systematic reviews of RCTs that evaluated the efficacy of LAIA glargine or detemir, compared to NPH insulin for T1D, assessing glycated hemoglobin (A1C) and hypoglycemia. Data sources included Pubmed, Cochrane Library, EMBASE and hand-searching. The methodological quality of studies was independently assessed by two reviewers, using AMSTAR and Jadad scale. We found 11 eligible systematic reviews that contained a total of 25 relevant clinical trials. Two reviewers independently abstracted data. RESULTS: We found evidence that LAIA are efficacious compared to NPH, with estimates showing a reduction in nocturnal hypoglycemia episodes (RR 0.66; 95% CI 0.57; 0.76) and A1C (95% CI 0.23; 0.12). No significance was found related to severe hypoglycemia (RR 0.94; 95% CI 0.71; 1.24). CONCLUSION: This study design has allowed us to carry out the most comprehensive assessment of RCTs on this subject, filling a gap in diabetes research. Our paper addresses a question that is important not only for decision makers but also for clinicians.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Regardless of the insulin delivery method (MDI vs CSII), glycemic control metrics, including A1C and CGM TIR, hypoglycemic events, QoL, and patient satisfaction are substantially improved when MDI or CSII is augmented with CGM, with better results when CSII is combined with CGM or integrated into AID systems, compared with using CGM.158,160,1129–1131”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1129]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews
Shea, B. J., Grimshaw, J. M., Wells, G. A., Boers, M., Andersson, N., Hamel, C., Porter, A. C., Tugwell, P., Moher, D., & Bouter, L. M. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-10 · Cited by 4,374
Research works printed but not linked: 10
- T William, 2016, American Diabetes Association standards of medical care in diabetes 2016, Diabetes Care, 39, S1
- A Szypowska, 2009, Better metabolic control, less hypoglycemia and less weight gain with insulin detemir versus NPH insulin in intensive insulin therapy for patients with type 1 diabetes. A meta-analysis, Diabetologia, 52, S387
- P Rossetti, 2003, Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime, Diabetes Care, 26, 1490, 10.2337/diacare.26.5.1490 · DOI · Paper page
- P Home, 2004, Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial, Diabetes Care, 27, 1081, 10.2337/diacare.27.5.1081 · DOI · Paper page
- P Home, 2003, Insulin detemir offers improved glycemic control, less weight gain, and flexible timing of administration compared to NPH insulin, Diabetes, 52, A122
- JD Russell, 2004, Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen, Clin Ther, 26, 724, 10.1016/s0149-2918(04)90072-0 · DOI · Paper page
- PC Bartley, 2008, Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial, Diabet Med, 25, 442, 10.1111/j.1464-5491.2007.02407.x · DOI · Paper page
- SL Bowker, 2005, Systematic review of indicators and measurements used in controlled studies of quality improvement for type 2 diabetes, Can J Diabetes, 29, 230
- DM Nathan, 2014, The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview, Diabetes care, 37, 9, 10.2337/dc13-2112 · DOI · Paper page
- RM Bergenstal, 2015, No difference in Major Adverse Cardiovascular Events (MACE plus) with Basal Insulin peglispro (BIL) vs comparator insulins in patients with type 1 or type 2 diabetes, Diabetologia, 58, S65
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
“Rapid-acting insulin analogs (lispro, glulisine, or aspart) and long-acting insulin analogs (glargine, detemir, or degludec) should be used first in patients with T1DM when treated with MDIs (RCT, General) [14,56-61].”
BackgroundHypoglycemia in diabetes: An update on pathophysiology, treatment, and prevention
Nakhleh, A., & Shehadeh, N. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i12.2036 · Cited by 154
Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review
Janež, A., Guja, C., Mitrakou, A., Lalic, N., Tankova, T., Czupryniak, L., Tabák, A. G., Prazny, M., Martinka, E., & Smircic-Duvnjak, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00743-7 · Cited by 177
Lind, M., Pivodic, A., Svensson, A.-M., Ólafsdóttir, A. F., Wedel, H., & Ludvigsson, J. (2019) · BMJ · doi:10.1136/bmj.l4894 · Cited by 175
Metadata
- Authors
- Laranjeira, F. O., de Andrade, K. R. C., Figueiredo, A. C. M. G., Silva, E. N., & Pereira, M. G.
- Affiliations
- Universidade de Brasília (BR)
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-04-12
- Volume
- 13
- Issue
- 4
- Pages
- e0194801
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5896894
- OpenAlex
- W2796961649
- Cited by
- 41
- References
- 83
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 12 · 2020: 6 · 2019: 12
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Americanae (AECID Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- RIUnB Institutional Repository (University of Brasília) (submittedVersion, cc-by)
- Funders
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Ministério da Educação
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- long-acting insulin analogues, type 1 diabetes, insulin glargine, insulin detemir, NPH insulin, HbA1c, hypoglycemia, nocturnal hypoglycemia, severe hypoglycemia, insulin therapy comparison
- MeSH terms
- Insulin Glargine, Insulin Detemir, Diabetes Mellitus, Type 1, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Regression Analysis, Models, Statistical, Randomized Controlled Trials as Topic, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1371/journal.pone.0194801
- The paper
- Laranjeira, F. O., de Andrade, K. R. C., Figueiredo, A. C. M. G., Silva, E. N., & Pereira, M. G. (2018). Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials. PLOS ONE. https://doi.org/10.1371/journal.pone.0194801
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.